VIDAZA® (Azacitidine) July 25, 2022July 25, 2022 RR FDA Approvals Myeloproliferative Disorders The FDA on May 20, 2022, approved VIDAZA® for pediatric patients with newly diagnosed Juvenile MyeloMonocytic Leukemia (JMML). VIDAZA® is a product of Celgene Corp. Related Posts:VIDAZA® plus VENCLEXTA® for Elderly patients with…DACOGEN® May Be Superior to VIDAZA® in Higher-Risk…Long Term Overall Survival Benefit with VIDAZA® plus…ONUREG® (Azacitidine tablets)TIBSOVO® and VIDAZA® Combo Improve Survival in…IDHIFA® plus VIDAZA® Significantly Improves Complete…
